US Liver Biopsy Market Research Report By Type (Percutaneous, Transjugular, Laparoscopic) - Forecast to 2035

US Liver Biopsy Market Overview

As per MRFR analysis, the US Liver Biopsy Market Size was estimated at 205.8 (USD Million) in 2023. The US Liver Biopsy Market Industry is expected to grow from 225.4(USD Million) in 2024 to 612.75 (USD Million) by 2035. The US Liver Biopsy Market CAGR (growth rate) is expected to be around 9.518% during the forecast period (2025 - 2035).

Key US Liver Biopsy Market Trends Highlighted

The US Liver Biopsy Market is shaped by several key market drivers, including the rising incidence of liver diseases, such as hepatitis c drugsand non-alcoholic fatty liver disease (NAFLD). As awareness of these conditions grows, public health initiatives in the US have emphasized the importance of early diagnosis and intervention, which increases the demand for liver biopsy procedures. Additionally, advancements in minimally invasive biopsy techniques are enhancing patient safety and comfort, thus driving more healthcare providers to adopt these procedures. Opportunities to be explored in the US market include the integration of artificial intelligence (AI) in diagnostic imaging, which could improve the accuracy and efficiency of liver biopsies.There is also a growing interest in non-invasive alternatives to traditional biopsies, which can offer safer and more convenient ways to diagnose liver conditions. 

This shift in focus opens avenues for research and development in innovative diagnostic tools that cater to the needs of both clinicians and patients. Trends in recent times indicate an increasing emphasis on personalized medicine in the US liver biopsy landscape. Healthcare providers are adopting tailored treatment plans based on individual patient profiles, leading to a more targeted approach in managing liver diseases. Furthermore, regulatory bodies in the US are working to streamline the approval processes for new biopsy techniques and devices, which could facilitate quicker access to advanced technologies for clinicians.Overall, the US Liver Biopsy Market is poised for growth, driven by emerging technologies, changing patient demographics, and evolving healthcare standards.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Liver Biopsy Market Drivers

Increasing Prevalence of Liver Diseases

The rise in liver diseases such as Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatitis is a significant driver for the US Liver Biopsy Market Industry. The American Liver Foundation states that between 25 to 30 percent of the U.S. population has NAFLD, which can lead to more serious liver conditions, including cirrhosis and liver cancer. This growing patient pool requires diagnostic tools like liver biopsy to monitor and assess liver health. With the National Institute of Diabetes and Digestive and Kidney Diseases estimating that approximately 4.5 million adults in the U.S.have chronic liver disease or cirrhosis, the demand for liver biopsy procedures will likely expand in the foreseeable future, further propelling the US Liver Biopsy Market.

Technological Advancements in Biopsy Procedures

Advancements in biopsy technologies, including imaging techniques such as ultrasound and MRI-guided biopsies, are enhancing the accuracy and safety of liver biopsies. These innovations have improved patient outcomes and reduced procedural risks. Research from the Radiological Society of North America has shown that image-guided biopsy procedures can diminish complication rates to as low as 1%. As the technology continues to evolve, healthcare providers are more inclined to adopt these methods, contributing to the growth of the US Liver Biopsy Market Industry.

Increased Awareness and Screening for Liver Health

There is a growing awareness of liver health among the general public, which is driving more individuals to seek screening and diagnostic procedures. The U.S. Centers for Disease Control and Prevention has initiated public health campaigns aimed at liver disease prevention and early detection, which stresses the importance of routine screenings for at-risk populations. This heightened awareness leads to a greater number of patients being referred for liver biopsies, thus increasing the demand within the US Liver Biopsy Market.

Rising Demand for Accurate Diagnostic Tools

An increasing focus on accurate diagnosis for liver diseases is spurring the demand for liver biopsy procedures. Clinicians and healthcare providers are recognizing the limitations of non-invasive tests, leading to a higher reliance on liver biopsies for definitive diagnosis. The American Gastroenterological Association has reported that liver biopsies remain the gold standard for assessing liver fibrosis. As more healthcare professionals advocate for precise diagnostic methods, the US Liver Biopsy Market Industry is expected to experience significant growth.

US Liver Biopsy Market Segment Insights

Liver Biopsy Market Type Insights

The US Liver Biopsy Market segmentation by Type highlights the diverse approaches utilized for obtaining liver tissue samples, which include Percutaneous, Transjugular, and Laparoscopic techniques. Percutaneous biopsy, involving needle insertion through the skin to reach the liver, is one of the most common methods due to its minimally invasive nature and efficiency in diagnosing conditions such as hepatitis and cirrhosis. This technique has gained significant traction in recent years, particularly given the growing prevalence of liver diseases in the US, which has, in part, driven increased demand for more accurate and reliable diagnostic procedures. Transjugular biopsy, on the other hand, is often employed in cases where patients have coagulopathy or ascites, allowing for safer access to liver tissue without risking complications that could arise with percutaneous methods. Given the diverse patient populations in the US and the complexity of liver conditions, the versatility of the Transjugular technique plays a crucial role in the clinical decision-making process, ensuring that the best approach is utilized for each individual patient. Meanwhile, Laparoscopic biopsy, often regarded as a gold standard for certain cases requiring direct visualization of liver lesions, combines diagnosis with potential therapeutic interventions. 

Its adoption reflects advancements in surgical techniques and technology, as well as a growing emphasis on providing comprehensive care in a single procedure. Overall, the Type segmentation of the US Liver Biopsy Market showcases the necessity for varied methods to cater to the diverse needs of patients and healthcare providers alike. With the increasing incidence of liver diseases and a rising focus on precision medicine in the US, these biopsy techniques are poised to play a vital role in enhancing diagnostic accuracy and improving patient outcomes. As the market evolves, each method’s unique advantages will contribute significantly to the overall growth of the US Liver Biopsy Market, underscoring the importance of continued innovation and development within the industry.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Liver Biopsy Market Key Players and Competitive Insights

The US Liver Biopsy Market showcases a landscape characterized by significant technological advancements and evolving clinical practices, leading to enhanced diagnostic precision and patient outcomes. This market is driven by an increasing prevalence of liver diseases, heightened awareness among healthcare professionals regarding the importance of early diagnosis, and the development of innovative biopsy techniques and devices. Competitive insights reveal a dynamic environment where well-established companies along with emerging players vie to capture market share through strategic initiatives such as product innovation, collaborations, and acquisitions. An emphasis on research and development is evident as companies strive to meet the growing demand for minimally invasive procedures aimed at liver health evaluation. This competitive intensity catalyzes improvement in methodologies and fosters a landscape conducive to better patient care and outcomes.

Hologic has carved a substantial niche within the US Liver Biopsy Market by leveraging its strengths in innovative medical devices aimed at improving diagnostic processes. With a robust portfolio of proprietary technologies focused on imaging and biopsy solutions, Hologic emphasizes precision and patient safety, which are crucial in liver biopsy procedures. The company is known for its commitment to advancing women’s health and is increasingly applying its expertise to liver health diagnostics. Hologic’s market presence is underscored by a strong distribution network and strategic partnerships that enhance its ability to deliver quality products to healthcare providers. By continually investing in research and development, Hologic aims to further solidify its competitive edge and address the specific needs of the healthcare market in the US while focusing on patient-centered care.

Merck also plays a prominent role in the US Liver Biopsy Market, shaping the competitive landscape through a range of key products and services designed for liver disease diagnosis and treatment. The company's strengths lie in its comprehensive research capabilities and robust product pipeline that includes a variety of diagnostic agents and biopsy solutions. Merck’s commitment to advancing liver health can be seen in its strategic collaborations and partnerships that facilitate innovative breakthroughs in the biopsy process. Moreover, the company actively engages in mergers and acquisitions to enhance its portfolio and market reach, ensuring its position at the forefront of the industry. With a firm presence in the US, Merck focuses on providing healthcare professionals with effective tools and technologies that contribute to improved patient outcomes in liver health management. As the company continues to innovate, it reinforces its stature as a key player in addressing the healthcare challenges associated with liver diseases.

Key Companies in the US Liver Biopsy Market Include

• Hologic


• Merck


• GE Healthcare


• BristolMyers Squibb


• Gilead Sciences


• Boston Scientific


• Medtronic


• Thermo Fisher Scientific


• Siemens Healthineers


• AbbVie


• Fujifilm Holdings


• Canon Medical Systems


• Cook Medical


• Becton Dickinson


• Aceto Corporation

US Liver Biopsy Market Industry Developments

The US Liver Biopsy Market has seen notable developments in recent months, particularly with advancements in minimally invasive techniques and imaging technologies. Companies such as Hologic and GE Healthcare are focusing on innovative biopsy methods that reduce patient discomfort while increasing diagnostic accuracy. Recently, Gilead Sciences reported a significant increase in their market valuation due to the growing emphasis on liver health and the rise in chronic liver diseases among the population. In terms of mergers and acquisitions, AbbVie completed the acquisition of Allergan in May 2020, with implications for expanding their liver disease portfolio, although it primarily targeted broader therapeutic areas. 

Similarly, Merck is noted for exploring partnerships to enhance their liver biopsy solutions. The competitive landscape is intensifying, with BristolMyers Squibb and Siemens Healthineers also investing significantly in Research and Development related to liver disease diagnostics. Over the past few years, the emphasis on accurate diagnosis of liver conditions, largely attributed to the rising obesity epidemic, has catalyzed the growth of companies within this sector, thereby impacting the overall market dynamics positively. These developments are critical, considering the increasing urgency for innovative and reliable liver assessment tools in the US healthcare framework.

US Liver Biopsy Market Segmentation Insights

Liver Biopsy Market Type Outlook

• Percutaneous


• Transjugular


• Laparoscopic

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	205.8(USD Million)
MARKET SIZE 2024	225.4(USD Million)
MARKET SIZE 2035	612.75(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	9.518% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Hologic, Merck, GE Healthcare, BristolMyers Squibb, Gilead Sciences, Boston Scientific, Medtronic, Thermo Fisher Scientific, Siemens Healthineers, AbbVie, Fujifilm Holdings, Canon Medical Systems, Cook Medical, Becton Dickinson, Aceto Corporation
SEGMENTS COVERED	Type
KEY MARKET OPPORTUNITIES	Growing prevalence of liver diseases, Advancements in biopsy techniques, Rising demand for minimally invasive procedures, Increasing awareness of liver health, Expanding geriatric population driving diagnostics
KEY MARKET DYNAMICS	growing prevalence of liver diseases, advancements in biopsy techniques, increasing demand for minimally invasive procedures, rising awareness and education, supportive reimbursement policies
COUNTRIES COVERED	US